

WINNING THE WAR AGAINST CANCER

MONDAY JUNE 25, 2018

8:30



Welcome and opening remarks

The 10th Anniversary of the WIN Consortium: lessons and perspectives

Richard L. Schilsky, Chairman WIN Consortium, American Society of Clinical Oncology (ASCO®), USA

8:50



Opening Lecture: WINTHER trial

Razelle Kurzrock, University of California San Diego (UCSD), USA

PRESIDENTIAL SESSION 1: THE CHALLENGES OF BUILDING REAL COOPERATION TO IMPLEMENT PRECISION ONCOLOGY PROGRAMS: A LONG AND WINDING ROAD

Chairs: *Richard L. Schilsky, ASCO, USA, Chairman of WIN Consortium; Jean-Charles Soria, MedImmune, USA*

9:20



Keynote Lecture: The TAPUR family of clinical trials: building a global data sharing platform in Precision Oncology

Richard L. Schilsky, American Society of Clinical Oncology (ASCO), USA

9:50



Making Cancer History all together

Stephen M. Hahn, The University of Texas MD Anderson Cancer Center (UT-MDACC), USA

10:20



U.S. National Cancer Institute perspective on Precision Oncology

James H. Doroshow, National Cancer Institute (NCI), USA

10:50 Coffee break, networking

11:15



Beyond standard of care: the next steps of Precision Oncology - an ESMO perspective

Josep Taberero, Vall d'Hebron Institute of Oncology (VHIO), Spain. President European Society for Medical Oncology (ESMO), Switzerland

11:45



The future of the EU Framework programmes for research and innovation

Cornelius Schmaltz, Head of Unit Health Research Strategy, Directorate General for Research and Innovation at the European Commission in Brussels, Belgium

12:15

Open Forum and Debate with the audience: The key issues of worldwide cooperation

- Technology and conceptual breakthroughs
- Industry or academic sponsored research
- Funding of clinical trials
- Publication policies

Moderators:

Lisa Hutchinson, Foundation for World Health (FWH), UK
Jean-Charles Soria, MedImmune, USA

Panel:

James H. Doroshow, NCI, USA
Stephen M. Hahn, UT-MDACC, USA
Richard L. Schilsky, ASCO, USA
Cornelius Schmaltz, European Commission, Belgium
Josep Taberero, VHIO, Spain, ESMO

13:15 Lunch break, poster viewing and networking

SESSION 2: THE NEXT FRONTIER OF THERAPEUTICS IN NEWLY DIAGNOSED PATIENTS: STANDARD OF CARE OR MODERN BIOMARKER DRIVEN PRECISION ONCOLOGY?

Chairs: *Razelle Kurzrock, UCSD, USA; Josep Taberero, VHIO, Spain, ESMO*

14:15



21st Century Medicine is transforming healthcare and the diagnosis and treatment of cancer

Leroy Hood, Institute for Systems Biology (ISB), USA

14:45



A new world of early diagnosis to defeat Non-Small Cell Lung Carcinoma (NSCLC); The WIN Consortium BOOSTER trial for identification and validation of new blood biomarkers for NSCLC

Amir Onn, Sheba Medical Center, Israel

15:00



Lessons from long-term survey of Stage I NSCLC

Harvey I. Pass, New York University (NYU), Langone Health, USA

15:15 Coffee break, networking

ORGANIZING COMMITTEE

CHAIRS:

John Mendelsohn (USA)
Razelle Kurzrock (USA)

MEMBERS:

Lisa Hutchinson (UK)
Brian Leyland-Jones (USA)
Amir Onn (Israel)
Richard L. Schilsky (USA)
Chang-Sik Yu (South Korea)
Vladimir Lazar (France)
Catherine Bresson (France)

MONDAY JUNE 25, 2018 - CONTINUED

15:40



Keynote Lecture: Patients driving progress
Ellen V. Sigal, Friends of Cancer Research, USA

16:10



Newly diagnosed breast cancer at the frontier of Precision Oncology
Laura Esserman, University of California San Francisco (UCSF), USA

17:40 **Open forum and debate with the audience: Next frontiers of therapeutics**

Moderators:

Razelle Kurzrock, UCSD, USA
Josep Taberbero, VHIO, Spain, ESMO

Panel:

Laura Esserman, UCSF, USA
Leroy Hood, Institute for Systems Biology (ISB), USA
Amir Onn, Sheba Medical Center, Israel
Harvey I. Pass, NYU Langone Health, USA
Ellen V. Sigal, Friends of Cancer Research, USA

17:40

WELCOME RECEPTION, NETWORKING AND POSTER VIEWING running at the same time as

18:30

MEET THE PROFESSOR sessions to choose from:

- Meeting 1:** *Razelle Kurzrock, University of California San Diego (UCSD), USA*
Josep Taberbero, Vall d'Hebron (VHIO), Spain; President (ESMO), Switzerland
- Meeting 2:** *James H. Doroshow, National Cancer Institute (NCI), USA*
Richard L. Schilsky, American Society of Clinical Oncology (ASCO), USA
- Meeting 3:** *Francesco De Lorenzo, European Cancer Patient Coalition (ECPC), Belgium*
Ellen V. Sigal, Friends of Cancer Research, USA
- Meeting 4:** *Carl H. June, Perelman School of Medicine, USA*
Laura Esserman, University of California San Francisco, USA
- Meeting 5:** *Jean-Charles Soria, MedImmune, USA*
Apostolia-Maria Tsimberidou, University of Texas, MD Anderson Cancer Center (UT-MDACC), USA

19:00

Gala dinner (departure 19:30)

TUESDAY JUNE 26, 2018

SESSION 3: **DISRUPTIVE CONCEPTS AND CLINICAL TRIALS SHIFTING THE PARADIGM OF PRECISION ONCOLOGY**

Chairs: Carl H. June, Perelman School of Medicine, USA; Richard L. Schilsky, ASCO, USA

8:30



Keynote Lecture: Combinations of monoclonal antibodies overcome resistance to drugs
Yosef Yarden, Weizmann Institute of Science, Israel

8:55



The first targeted agents tri-therapy combination trial in first therapeutic line of metastatic NSCLC: the WIN Consortium SPRING_01 trial
Razelle Kurzrock, University of California San Diego (UCSD), USA

9:20



The challenges of combining targeted therapies in biomarker driven Precision Oncology – a Pharma perspective
Jean-François Martini, Pfizer Inc., USA

9:45



MyPathway study: a novel precision oncology multiple basket trial
Mary Beattie, Genentech, USA


10:10

Coffee break, networking


TUESDAY JUNE 26, 2018 - CONTINUED

SESSION 4: **NEW CONCEPTS AND THERAPEUTICS AVENUES IN PRECISION ONCOLOGY**

Chair: Alan Spatz, McGill Segal Cancer Center, Canada

10:40  **Keynote Lecture:** Precision CAR T-cells therapeutics
Carl H. June, Perelman School of Medicine, 2017 David A. Karnofsky Memorial Award ASCO, USA

11:05  Immunotherapies turning cold into hot tumors
Jean-Charles Soria, MedImmune, USA

11:30  Precision Oncology approaches for immunotherapy
Eric Rubin, Merck Sharp & Dohme, USA

11:55  Early development in oncology: Are the MTD and monotherapy efficacy still the best objectives?
Giorgio Massimini, Merck KGaA, Germany

12:20 Open forum and debate with the audience: The future of drug development for Precision Oncology

Moderators:

*Alan Spatz, McGill Segal Cancer Centre, Canada
Phillip Febbo, Illumina, USA*


Panel:


*Carl H. June, Perelman School of Medicine, USA
Jean-François Martini, Pfizer Inc., USA
Giorgio Massimini, Merck KGaA, Germany
Eric Rubin, Merck Sharp & Dohme, USA
Richard L. Schilsky, ASCO, USA*

13:00 Lunch break, poster viewing and networking

SESSION 5: **CHALLENGES OF PRECISION ONCOLOGY**

Chair: Vladimir Lazar, WIN Consortium, France

14:00  Implementing Precision Medicine in Oncology: The IMPACT Clinical Trials at MD Anderson
Apostolia-Maria Tsimberidou, University of Texas, MD Anderson Cancer Center (UT-MDACC), USA

14:50  The 'greatest hits' of Precision Oncology: the view from the newsroom
Bernadette Toner, GenomeWeb, USA

15:15  Patients' access to Precision Oncology
Francesco De Lorenzo, European Cancer Patient Coalition (ECPC), Belgium

15:40 Coffee break, networking

16:00 2 best posters presentations

16:30 SESSION 6: **CELEBRATION OF THE LIFE AND ACHIEVEMENTS OF PROFESSOR THOMAS TURSZ**

Vladimir Lazar, WIN Consortium, France

17:00 *Jacques Raynaud, Fondation ARC, France*

